Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Hodge

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Provider (Washington, D.C.)|January 19, 2008
Culture change from the top downJames W Hodge
International Journal of Molecular Sciences|May 27, 2023
Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination StrategiesDavid Zahavi, James W Hodge
Seminars in Oncology|May 19, 2012
Introduction: Therapeutic cancer vaccinesJeffrey Schlom, James W Hodge
Molecular Therapy Oncolytics|November 11, 2021
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapyKellsye P Fabian, James W Hodge
Journal of Neurosurgery|July 29, 2017
A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximabRika Fujii, Jeffrey Schlom, James W Hodge
Vaccine|May 20, 2009
Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenJames W Hodge, Jack Higgins, Jeffrey Schlom
Cancer Immunology, Immunotherapy : CII|February 24, 2007
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responsesMala Chakraborty, Jeffrey Schlom, James W Hodge
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responsesChie Kudo-Saito, Jeffrey Schlom, James W Hodge
International Journal of Cancer|June 3, 2011
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyBenedetto Farsaci, Jack P Higgins, James W Hodge
Frontiers in Oncology|September 9, 2021
From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor MicroenvironmentKellsye P Fabian, Benjamin Wolfson, James W Hodge
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Provider (Washington, D.C.)|January 19, 2008
Culture change from the top downJames W Hodge
International Journal of Molecular Sciences|May 27, 2023
Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination StrategiesDavid Zahavi, James W Hodge
Seminars in Oncology|May 19, 2012
Introduction: Therapeutic cancer vaccinesJeffrey Schlom, James W Hodge
Molecular Therapy Oncolytics|November 11, 2021
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapyKellsye P Fabian, James W Hodge
Journal of Neurosurgery|July 29, 2017
A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximabRika Fujii, Jeffrey Schlom, James W Hodge
Vaccine|May 20, 2009
Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenJames W Hodge, Jack Higgins, Jeffrey Schlom
Cancer Immunology, Immunotherapy : CII|February 24, 2007
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responsesMala Chakraborty, Jeffrey Schlom, James W Hodge
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responsesChie Kudo-Saito, Jeffrey Schlom, James W Hodge
International Journal of Cancer|June 3, 2011
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyBenedetto Farsaci, Jack P Higgins, James W Hodge
Frontiers in Oncology|September 9, 2021
From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor MicroenvironmentKellsye P Fabian, Benjamin Wolfson, James W Hodge
Pageof 16